TY - JOUR
T1 - Accelerated cell cycle progression of human regulatory T cell-like cell line caused by continuous exposure to asbestos fbers
AU - Lee, Suni
AU - Matsuzaki, Hidenori
AU - Maeda, Megumi
AU - Yamamoto, Shoko
AU - Kumagai-Takei, Naoko
AU - Hatayama, Tamayo
AU - Ikeda, Miho
AU - Yoshitome, Kei
AU - Nishimura, Yasumitsu
AU - Otsuki, Takemi
N1 - Funding Information:
This study was supported by the Private university Strategic Research Base Formation Support Project (2011 to 2016), kakenhi 15k08788, the Japanese Society for the Promotion of Science, and Research Grants from kawasaki Medical School (27B058, 26B53, 25B67, 24S4 and 23S6).
PY - 2017/1
Y1 - 2017/1
N2 - Asbestos exposure causes malignant tumors such as lung cancer and malignant mesothelioma. Based on our hypothesis in which continuous exposure to asbestos of immune cells cause reduction of antitumor immunity, the decrease of natural killer cell killing activity with reduction of NKp46 activating receptor expression, inhibition of cytotoxic T cell clonal expansion, reduced CXCR3 chemokine receptor expression and production of interferon-γ production in CD4+ T cells were reported using cell line models, freshly isolated peripheral blood immune cells from health donors as well as asbestos exposed patients such as pleural plaque and mesothelioma. In addition to these fndings, regulatory T cells (Treg) showed enhanced function through cell-cell contact and increased secretion of typical soluble factors, interleukin (IL)-10 and transforming growth factor (TGF)-β, in a cell line model using the MT-2 human polyclonal T cells and its sublines exposed continuously to asbestos fbers. Since these sublines showed a remarkable reduction of FoxO1 transcription factor, which regulates various cell cycle regulators in asbestosexposed sublines, the cell cycle progression in these sublines was examined and compared with that of the original MT-2 cells. Results showed that cyclin D1 expression was markedly enhanced, and various cyclin-dependent kinase-inhibitors were reduced with increased S phases in the sublines. Furthermore, the increase of cyclin D1 expression was regulated by FoxO1. The overall findings indicate that antitumor immunity in asbestos-exposed individuals may be reduced in Treg through changes in the function and volume of Treg.
AB - Asbestos exposure causes malignant tumors such as lung cancer and malignant mesothelioma. Based on our hypothesis in which continuous exposure to asbestos of immune cells cause reduction of antitumor immunity, the decrease of natural killer cell killing activity with reduction of NKp46 activating receptor expression, inhibition of cytotoxic T cell clonal expansion, reduced CXCR3 chemokine receptor expression and production of interferon-γ production in CD4+ T cells were reported using cell line models, freshly isolated peripheral blood immune cells from health donors as well as asbestos exposed patients such as pleural plaque and mesothelioma. In addition to these fndings, regulatory T cells (Treg) showed enhanced function through cell-cell contact and increased secretion of typical soluble factors, interleukin (IL)-10 and transforming growth factor (TGF)-β, in a cell line model using the MT-2 human polyclonal T cells and its sublines exposed continuously to asbestos fbers. Since these sublines showed a remarkable reduction of FoxO1 transcription factor, which regulates various cell cycle regulators in asbestosexposed sublines, the cell cycle progression in these sublines was examined and compared with that of the original MT-2 cells. Results showed that cyclin D1 expression was markedly enhanced, and various cyclin-dependent kinase-inhibitors were reduced with increased S phases in the sublines. Furthermore, the increase of cyclin D1 expression was regulated by FoxO1. The overall findings indicate that antitumor immunity in asbestos-exposed individuals may be reduced in Treg through changes in the function and volume of Treg.
KW - Asbestos
KW - Cell cycle
KW - Cyclin D1
KW - FoxO1
KW - Regulatory T cell
UR - http://www.scopus.com/inward/record.url?scp=85007583914&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85007583914&partnerID=8YFLogxK
U2 - 10.3892/ijo.2016.3776
DO - 10.3892/ijo.2016.3776
M3 - Article
C2 - 27878235
AN - SCOPUS:85007583914
SN - 1019-6439
VL - 50
SP - 66
EP - 74
JO - International Journal of Oncology
JF - International Journal of Oncology
IS - 1
ER -